Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral,… Read more
Pliant Therapeutics Inc (PLRX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.105x
Based on the latest financial reports, Pliant Therapeutics Inc (PLRX) has a cash flow conversion efficiency ratio of -0.105x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.08 Million) by net assets ($200.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pliant Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Pliant Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Pliant Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pliant Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Global Lights Acquisition Corp Ordinary Shares
NASDAQ:GLAC
|
-0.003x |
|
Bosch Home Comfort India Limited
NSE:BOSCH-HCIL
|
-0.180x |
|
Gyldendal A/S
CO:GYLD-B
|
0.262x |
|
Berjaya Corporation Berhad
PINK:BRYAF
|
-0.022x |
|
Lassila &Tikanoja Oyj
HE:LAT1V
|
0.070x |
|
Bhiraj Office Leasehold Real Estate Investment Trust
BK:BOFFICE
|
0.023x |
|
ReproCELL Incorporated
F:6RC
|
N/A |
|
Kernel Holding SA
F:0KE
|
0.006x |
Annual Cash Flow Conversion Efficiency for Pliant Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Pliant Therapeutics Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $304.08 Million | $-155.50 Million | -0.511x | -108.13% |
| 2023-12-31 | $473.58 Million | $-116.36 Million | -0.246x | +18.64% |
| 2022-12-31 | $313.34 Million | $-94.63 Million | -0.302x | +20.31% |
| 2021-12-31 | $199.06 Million | $-75.44 Million | -0.379x | -187.84% |
| 2020-12-31 | $283.06 Million | $-37.27 Million | -0.132x | -102.08% |
| 2019-12-31 | $-435.00K | $-2.75 Million | 6.322x | -80.32% |
| 2018-12-31 | $-882.00K | $-28.33 Million | 32.118x | +738.60% |
| 2017-12-31 | $3.37 Million | $-16.92 Million | -5.029x | -- |